Carcinoma, Medullary

A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)

Drugs by status

Approved for this indication (3)

vandetanib
Selpercatinib
pralsetinib

Phase 2 trials (1)

fluorodopa

Organizations

Organization Involved with Phase 2 Indications (12)

Bristol-Myers Squibb
Merck
Genzyme
Sanofi
Epizyme, Inc.
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
University of Washington
Ohio State University
Mayo Clinic
University of Chicago
University of Texas at Houston

Organization Involved with Phase 1 Indications (6)

Wyeth
National Institutes of Health (NIH)
Temple University
University of Southern California
Vanderbilt University
Yeshiva University

Organization Involved with Other Experimental Indications (2)

Southwest Oncology Group
City of Hope National Medical Center